Authors:
Klára Piukovics University of Szeged

Search for other papers by Klára Piukovics in
Current site
Google Scholar
PubMed
Close
,
Gabriella Terhes University of Szeged

Search for other papers by Gabriella Terhes in
Current site
Google Scholar
PubMed
Close
,
Andrea Lázár University of Szeged

Search for other papers by Andrea Lázár in
Current site
Google Scholar
PubMed
Close
,
Flóra Tímár University of Szeged

Search for other papers by Flóra Tímár in
Current site
Google Scholar
PubMed
Close
,
Zita Borbényi University of Szeged

Search for other papers by Zita Borbényi in
Current site
Google Scholar
PubMed
Close
, and
Edit Urbán University of Szeged

Search for other papers by Edit Urbán in
Current site
Google Scholar
PubMed
Close
Open access

From year to year, it is important to get an overview of the occurrence of causative agents in febrile neutropenic patients to determine the empiric treatment. Thus our aims were to evaluate a four-year period regarding the prevalence of bloodstream infections and the most important causative agents. During this period, 1,361 patients were treated in our hematology ward because of various hematological disorders. 812 febrile episodes were recorded in 469 patients. At that time, 3,714 blood culture (BC) bottles were sent for microbiological investigations, 759 of them gave positive signal. From the majority of positive blood culture bottles (67.1%), Gram-positive bacteria, mainly coagulase-negative staphylococci (CNS), were grown. Gram-negative bacteria were isolated from 32.9% of the positive blood culture bottles, in these cases the leading pathogen was Escherichia coli. The high prevalence of CNS was attributed to mainly contamination, while lower positivity rate for Gram-negative bacteria was associated with the use of broad-spectrum empiric antibiotic treatment.

  • 1.

    Crawford J , Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new direction for its management. Cancer 100, 228237 (2004)

    • Search Google Scholar
    • Export Citation
  • 2.

    Madani TA : Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 28, 367373 (2000)

    • Search Google Scholar
    • Export Citation
  • 3.

    Peters RPH , van Agtmael MA, Danner SA, Savelkoul PHM, Vandenbroucke-Grauls CMJE: New developments in the diagnosis of bloodstream infections. Lancet Infect Dis 4, 751760 (2004)

    • Search Google Scholar
    • Export Citation
  • 4.

    Schimpff S , Satterlee W, Young VM et al.: Emipiric therapy with carbenicliin and gentamicin for febrile patients with cancer an granulocytopenia. N Engl J Med 284, 10611065 (1971)

    • Search Google Scholar
    • Export Citation
  • 5.

    Baden LR : Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353, 10521054 (2005)

  • 6.

    Hammond SP , Baden LR: Antibiotic prophylaxis for patients with acute leukemia. Leuk Lymphoma 49, 183193 (2008)

  • 7.

    Hughes WT , Armstrong D, Bodey GP et al.: Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Inf Dis. 34, 730751 (2002)

    • Search Google Scholar
    • Export Citation
  • 8.

    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI document M100-S15 (ISBN 1-56238-556-9)

    • Search Google Scholar
    • Export Citation
  • 9.

    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. CLSI document M100-S16 (ISBN 1-56238-588-7)

    • Search Google Scholar
    • Export Citation
  • 10.

    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI document M100-S17 (ISBN 1-56238-625-5)

    • Search Google Scholar
    • Export Citation
  • 11.

    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI document M100-S18 (ISBN 1-56238-653-0)

    • Search Google Scholar
    • Export Citation
  • 12.

    Mermel LA , Allon M, Bouza E et al.: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49, 145 (2009)

    • Search Google Scholar
    • Export Citation
  • 13.

    Keng MK , Sekeres MA: Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep 8, 370378 (2013)

  • 14.

    Bodey GP . Buckley M, Sathe YS, Freireich EY: Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 64, 328340 (1966)

    • Search Google Scholar
    • Export Citation
  • 15.

    Syrjala H , Ohtonen P, Kinnunen U, Raty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itala-Remes M, Silvennoinen R, Koistinen P, Finnish Leukemia Group: Bloodstream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 29, 12111218 (2010)

    • Search Google Scholar
    • Export Citation
  • 16.

    Ramphal R : Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39, 2531 (2004)

    • Search Google Scholar
    • Export Citation
  • 17.

    Klastersky J , Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesamns M: Bacteremia in febrile neutropenic cancer patients. Int J Antimicrob Ag 30S, S51S59 (2007)

    • Search Google Scholar
    • Export Citation
  • 18.

    Viscoli C , Cometta A, Kern WV et al.: Piperacillin–tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 12, 212216 (2006)

    • Search Google Scholar
    • Export Citation
  • 19.

    Winston DJ , Lazarus HM, Beveridge RA et al.: Randomized, double-blind, multicentre trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 32, 381390 (2001)

    • Search Google Scholar
    • Export Citation
  • 20.

    DelFavero A , Menichetti F, Martino P et al.: A multicentre, double-bind, placebo-controlled trial comparing piperacillin–tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33, 12951301 (2001)

    • Search Google Scholar
    • Export Citation
  • 21.

    Cordonnier C , Buzyn A, Leverger G et al.: Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 36, 149158 (2003)

    • Search Google Scholar
    • Export Citation
  • 22.

    Picazo JJ : Management of the febrile neutropenic patient: a consensus conference. Clin Infect Dis 39, 16 (2004)

  • Collapse
  • Expand

Senior editors

Editor(s)-in-Chief: Dunay, Ildiko Rita, Prof. Dr. Pharm, Dr. rer. nat., University of Magdeburg, Germany

Editor(s)-in-Chief: Heimesaat, Markus M., Prof. Dr. med., Charité - University Medicine Berlin, Germany

Editorial Board

  • Berit Bangoura, Dr. DVM. PhD,  University of Wyoming, USA
  • Stefan Bereswill, Prof. Dr. rer. nat., Charité - University Medicine Berlin, Germany
  • Dunja Bruder, Prof. Dr. rer. nat., University of Magdeburg, Germany
  • Jan Buer, Prof. Dr. med., University of Duisburg, Germany
  • Edit Buzas, Prof. Dr. med., Semmelweis University, Hungary
  • Renato Damatta, Prof. PhD, UENF, Brazil
  • Maria Deli, MD, PhD, DSc, Biological Research Center, HAS, Hungary
  • Olgica Djurković-Djaković, Prof. Phd, University of Belgrade, Serbia
  • Jean-Dennis Docquier, Prof. Dr. med., University of Siena, Italy
  • Zsuzsanna Fabry, Prof. Phd, University of Washington, USA
  • Ralf Ignatius, Prof. Dr. med., Charité - University Medicine Berlin, Germany
  • Achim Kaasch, Prof. Dr. med., Otto von Guericke University Magdeburg, Germany
  • Oliver Liesenfeld, Prof. Dr. med., Inflammatix, USA
  • Matyas Sandor, Prof. PhD, University of Wisconsin, USA
  • Ulrich Steinhoff, Prof. PhD, University of Marburg, Germany
  • Michal Toborek, Prof. PhD, University of Miami, USA
  • Susanne A. Wolf, PhD, MDC-Berlin, Germany

 

Dr. Dunay, Ildiko Rita
Magdeburg, Germany
E-mail: ildiko.dunay@med.ovgu.de

Indexing and Abstracting Services:

  • PubMed Central
  • Scopus
  • ESCI
  • CABI
  • CABELLS Journalytics

 

2023  
Web of Science  
Total Cites
WoS
674
Journal Impact Factor 3.3
Rank by Impact Factor

Q2

Impact Factor
without
Journal Self Cites
3.1
5 Year
Impact Factor
3.2
Scimago  
Scimago
H-index
15
Scimago
Journal Rank
0.601
Scimago Quartile Score Microbiology (medical) (Q2)
Microbiology (Q3)
Immunology and Allergy (Q3)
Immunology (Q3)
Scopus  
Scopus
Cite Score
5.0
Scopus
CIte Score Rank
Microbiology (medical) Q2
Scopus
SNIP
0.832

 

European Journal of Microbiology and Immunology
Publication Model Gold Open Access
Online only
Submission Fee none
Article Processing Charge 900 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Gold Open Access
Purchase per Title  

European Journal of Microbiology and Immunology
Language English
Size A4
Year of
Foundation
2011
Volumes
per Year
1
Issues
per Year
4
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2062-509X (Print)
ISSN 2062-8633 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Sep 2024 0 28 14
Oct 2024 0 88 11
Nov 2024 0 49 4
Dec 2024 0 25 2
Jan 2025 0 46 7
Feb 2025 0 30 11
Mar 2025 0 0 0